Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer

The purpose of this study was to evaluate the efficacy and safety of a novel oral anticancer fluoropyrimidine derivative, S-1, in patients receiving initial chemotherapy for unresectable, advanced non-small-cell lung cancer (NSCLC). Between June 1996 and July 1998, 62 patients with NSCLC who had not...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawahara, M, Furuse, K, Segawa, Y, Yoshimori, K, Matsui, K, Kudoh, S, Hasegawa, K, Niitani, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375091/
https://www.ncbi.nlm.nih.gov/pubmed/11592762
http://dx.doi.org/10.1054/bjoc.2001.2031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375091/
https://www.ncbi.nlm.nih.gov/pubmed/11592762
http://dx.doi.org/10.1054/bjoc.2001.2031

Ejemplares similares